Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy.

Cerebrospinal fluid (CSF) Narcolepsy Single-cell RNA sequencing (scRNAseq) T cells Transcriptomics

Journal

Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164

Informations de publication

Date de publication:
24 Apr 2024
Historique:
received: 21 10 2023
revised: 23 03 2024
accepted: 16 04 2024
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 25 4 2024
Statut: aheadofprint

Résumé

Narcolepsy is a rare cause of hypersomnolence and may be associated or not with cataplexy, i.e. sudden muscle weakness. These forms are designated narcolepsy-type 1 (NT1) and -type 2 (NT2), respectively. Notable characteristics of narcolepsy are that most patients carry the HLA-DQB1*06:02 allele and NT1-patients have strongly decreased levels of hypocretin-1 (synonym orexin-A) in the cerebrospinal fluid (CSF). The pathogenesis of narcolepsy is still not completely understood but the strong HLA-bias and increased frequencies of CD4

Identifiants

DOI: 10.1016/j.jaut.2024.103234 PMID: 38663202
pubmed: 38663202
pii: S0896-8411(24)00068-4
doi: 10.1016/j.jaut.2024.103234
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103234

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Alina Huth (A)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany; Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.

Ikram Ayoub (I)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), University of Toulouse, CNRS, INSERM, Toulouse, France.

Lucie Barateau (L)

Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, Institute for Neurosciences of Montpellier INM, INSERM, University of Montpellier, Montpellier, France.

Lisa Ann Gerdes (LA)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany; Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany; Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.

Dany Severac (D)

GenomiX, MGX, BioCampus Montpellier, CNRS, INSERM, Univ. Montpellier, F-34094, Montpellier, France.

Stefan Krebs (S)

Laboratory for Functional Genome Analysis (LAFUGA), Gene Center of the LMU, Munich, Germany.

Helmut Blum (H)

Laboratory for Functional Genome Analysis (LAFUGA), Gene Center of the LMU, Munich, Germany.

Hayrettin Tumani (H)

Department of Neurology, University Hospital Ulm, Ulm, Germany.

Jürgen Haas (J)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Brigitte Wildemann (B)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Tania Kümpfel (T)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany; Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.

Eduardo Beltrán (E)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany; Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany; Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.

Roland S Liblau (RS)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), University of Toulouse, CNRS, INSERM, Toulouse, France.

Yves Dauvilliers (Y)

Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital, Institute for Neurosciences of Montpellier INM, INSERM, University of Montpellier, Montpellier, France.

Klaus Dornmair (K)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany; Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany; Munich Cluster of Systems Neurology (SyNergy), Munich, Germany. Electronic address: Klaus.Dornmair@med.uni-muenchen.de.

Classifications MeSH